EP Patent

EP2180044A1 — Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity

Assigned to Roche Glycart AG · Expires 2010-04-28 · 16y expired

What this patent protects

The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cel…

USPTO Abstract

The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.

Drugs covered by this patent

Patent Metadata

Patent number
EP2180044A1
Jurisdiction
EP
Classification
—
Expires
2010-04-28
Drug substance claim
No
Drug product claim
No
Assignee
Roche Glycart AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.